{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:00:22Z","timestamp":1793041222418,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca M\u00f6lndal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jchf.2023.04.017","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T14:02:46Z","timestamp":1687356166000},"page":"1320-1332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Mortality, Outcomes, Costs, and Use of\u00a0Medicines Following a First Heart\u00a0Failure\u00a0Hospitalization"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-0253","authenticated-orcid":false,"given":"Biykem","family":"Bozkurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Adamsson Eryd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3967","authenticated-orcid":false,"given":"Johan","family":"Bodeg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Khordoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Thuresson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2023.04.017_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/heartjnl-2022-321702","article-title":"Prevalence, outcomes and costs of a contemporary, multinational population with heart failure","volume":"109","author":"Norhammar","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2023.04.017_bib2","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jchf.2023.04.017_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-of-illness studies in heart failure: a systematic review 2004-2016","volume":"18","author":"Lesyuk","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jchf.2023.04.017_bib4","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.017_bib5","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2023.04.017_bib6","first-page":"1","article-title":"Heart failure drug treatment\u2013inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.04.017_bib7","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/ejhf.2620","article-title":"Use of\u00a0guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and\u00a0persistence","volume":"24","author":"Janse","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ejhf.2483","article-title":"Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata","volume":"24","author":"Stolfo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib9","first-page":"15","article-title":"Evaluating implementation approaches in heart failure: ripe for rEVOLUTION","volume":"11","author":"Bhatt","year":"2023","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.04.017_bib10","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib11","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/ejhf.2725","article-title":"Association between heart failure quality of care and mortality: a population-based cohort study using nationwide registries","volume":"24","author":"Batra","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/ejhf.762","article-title":"Association between enrolment in a heart failure quality registry and subsequent mortality\u2014a nationwide cohort study","volume":"19","author":"Lund","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study","volume":"22","author":"Birkeland","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jchf.2023.04.017_bib14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/dom.14698","article-title":"Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries","volume":"24","author":"Norhammar","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jchf.2023.04.017_bib15","article-title":"Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: the CaReMe CKD study","volume":"20","author":"Sundstrom","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jchf.2023.04.017_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jchf.2023.04.017_bib17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ejhf.1210","article-title":"Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan","volume":"20","author":"Nagai","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib18","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart\u00a0Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib19","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0735-1097(00)00995-5","article-title":"Is the prognosis of heart failure improving?","volume":"36","author":"Khand","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.017_bib20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.04.017_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.04.017_bib22","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1002\/ehf2.12883","article-title":"Implementation of sacubitril\/valsartan in Sweden: clinical characteristics, titration patterns, and determinants","volume":"7","author":"Fu","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/ehjqcco\/qcab019","article-title":"Utilization of sacubitril\/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry","volume":"8","author":"Zeymer","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jchf.2023.04.017_bib24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.04.017_bib25","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.04.017_bib26","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.04.017_bib27","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib28","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cardfail.2022.04.011","article-title":"Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population","volume":"28","author":"Thorvaldsen","year":"2022","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib29","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ejhf.2131","article-title":"Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart\u00a0Failure Registry","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib30","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2023.04.017_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of beta-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jchf.2023.04.017_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006213","article-title":"Heart rate and heart failure with preserved ejection fraction: time to slow beta-blocker use?","volume":"12","author":"Meyer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib33","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care","volume":"23","author":"Trevisan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib34","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/ejhf.1793","article-title":"Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart\u00a0Failure Long-Term Registry","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib35","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart\u00a0Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib36","first-page":"881","article-title":"What to and not to monitor for uptitration of GDMT in patients with heart failure: the case for patient self-uptitration of GDMT","volume":"10","author":"Bozkurt","year":"2022","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.04.017_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijcard.2021.09.013","article-title":"Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: observations from the Swedish Heart\u00a0Failure Registry","volume":"343","author":"Kapelios","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2023.04.017_bib38","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/ejhf.2530","article-title":"Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality","volume":"24","author":"Schrage","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.017_bib39","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.jacc.2022.03.338","article-title":"Electronic alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial","volume":"79","author":"Ghazi","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.017_bib40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/heartjnl-2022-321497","article-title":"Sequencing of medical therapy in heart failure with a reduced ejection fraction","volume":"109","author":"Savage","year":"2023","journal-title":"Heart"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923002342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923002342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:04:00Z","timestamp":1761973440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177923002342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2213177923002342"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2023.04.017","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality, Outcomes, Costs, and Use of\u00a0Medicines Following a First Heart\u00a0Failure\u00a0Hospitalization","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2023.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}